Searched for
ARCH PHARMA CASE
NCLT rejects JM Financial Asset Reconstruction's plea in Arch Pharmalabs case...The National Company Law Tribunal dismissed JM Financial Asset Reconstruction's application to intervene in an insolvency resolution applic...- India imposes anti-dumping duty on ursodiolAn industry expert said China had been “unfairly dumping” the chemical, which had brought down its local price from $350 a kg in 2018 to $1...
- Career goals to succeed in 2018The ability to adapt will determine future success. Here is a lowdown on the state of jobs in a slew of sectors, and how employees can adap...
- Top drug makers like Sun Pharma, Torrent, Cipla working on quality standards at manufacturing facilitiesArch rivals are grouping to look for a lasting solution to what external subject experts call “deeply ingrained culture issue”.
- Cipla, Glenmark in race for hived-off Teva-Allergan generics in USSources indicated that Indian drug makers will be keen to buy the generic portfolio on offer, which could be valued at a minimum of $500 mi...
- Startups challenge listed cos' valuations; At $16 bn, Flipkart Beats Indian Oil Corporation, Tata MotorsFlipkart, enjoys a valuation that's more than that of brick-and-mortar giants like Indian Oil Corporation ($14.3 billion), Tata Motors ($13...
- UBI slaps winding up petition against Kingfisher AirlinesThe State Bank of India had said earlier that it was also exploring ways to declare Vijay Mallya as a willful defaulter.
- United Bank of India labels Bilcare as 'wilful defaulter' in a 'war on NPAs', to send winding-up noticeUnited Bank of India has taken action against four loan defaulters in an attempt to reduce its non-performing loans.
- CCI approves Mitsui's 26% stake buy in Arch PharmalabsCompetition Commission of India (CCI) has approved Japanese firm Mitsui's proposed takeover of 26.71 per cent stake in domestic biopharmace...
- PwC's fate Hangs in BalanceThe falsification of accounts by Satyam for the past several years has put a question mark on the very survival of its auditor, Pricewaterh...
- Ranbaxy strikes deal on Nexium with AstraZenecaRanbaxy has entered into a series of out-of-court settlements with AstraZeneca with estimates of a revenue upside of $1.25-1.5 billion. Go ...
- Ranbaxy can't pop Orchid easilySolrex will have to fork out an extra Rs 400-500 crore to buy a further 20% stake in case it comes with an open offer.
- NGO to seek compulsory licensing of cancer drugsHealthcare groups, campaigning for access to medicines, are going all out in their fight against drug patents in India.
- Pfizer again sues Ranbaxy over LipitorPfizer has filed two separate patent infringement cases against Ranbaxy in a bid to extend the exclusivity of its $13-billion anti-choleste...
- Post Budget: Pharma unlikely to get actual benefitThe industry feels that govt's support in the form of apparent attractive tax incentives would do very little to provide growth stimulus. H...
- Cipla scores a generic win over RocheThe Delhi HC rejected an injunction plea by Swiss drug major Roche to prevent Cipla from manufacturing generic versions of anti-cancer drug...
- Govt backs drug regulator's move to fix Roscillin priceIn what could be a setback for Ranbaxy and a few other companies, the government has endorsed the pharma price regulator’s decision to fix ...
- Govt to ensure price cut in non-controlled drugsFollowing finance minister’s decision to slash customs duty on some of the medicines and excise duty on all, drug makers will get over a fo...
- Patently yours: Small firms desperately need patentsSmall firms often do not have resources to develop their intellectual property. Patents give them something they desperately need: reputati...
- Strategic movesFor companies big and small CRM has become a necessity - SMEs in particular have realised its vast importance.
Load More
